Cited by 431Liver physiology and pathologyChemokine receptors and signalingCardiac Fibrosis and Remodeling

CCR1 and CCR5 promote hepatic fibrosis in mice

Open access
Seki, Ekihiro, De Minicis, Samuele, Gwak, Geum-Youn, Kluwe, Johannes, Inokuchi, Sayaka, Bursill, Christina A., Llovet, Josep M., Brenner, David A. +1 more·2009·Journal of Clinical Investigation

Abstract

Hepatic fibrosis develops as a response to chronic liver injury and almost exclusively occurs in a proinflammatory environment. However, the role of inflammatory mediators in fibrogenic responses of the liver is only poorly understood. We therefore investigated the role of CC chemokines and their receptors in hepatic fibrogenesis. The CC chemokines MIP-1alpha, MIP-1beta, and RANTES and their receptors CCR1 and CCR5 were strongly upregulated in 2 experimental mouse models of fibrogenesis. Neutralization of CC chemokines by the broad-spectrum CC chemokine inhibitor 35k efficiently reduced hepatic fibrosis, and CCR1- and CCR5-deficient mice displayed substantially reduced hepatic fibrosis and macrophage infiltration. Analysis of fibrogenesis in CCR1- and CCR5-chimeric mice revealed that CCR1 mediates its profibrogenic effects in BM-derived cells, whereas CCR5 mediates its profibrogenic effects in resident liver cells. CCR5 promoted hepatic stellate cell (HSC) migration through a redox-sensitive, PI3K-dependent pathway. Both CCR5-deficient HSCs and CCR1- and CCR5-deficient Kupffer cells displayed strong suppression of CC chemokine-induced migration. Finally, we detected marked upregulation of RANTES, CCR1, and CCR5 in patients with hepatic cirrhosis, confirming activation of the CC chemokine system in human fibrogenesis. Our data therefore support a role for the CC chemokine system in hepatic fibrogenesis and suggest distinct roles for CCR1 and CCR5 in Kupffer cells and HSCs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci37444

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F.
Affiliations
  • Columbia University (US)
  • University of California San Diego (US)
  • University of Oxford (GB)
  • Universitat de Barcelona (ES)
Venue
Journal of Clinical Investigation
Published
2009-06-15
Volume
119
Issue
7
Pages
1858-70
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2055176387
Cited by
431
References
3
Citations by year
2026: 7 · 2025: 8 · 2024: 14 · 2023: 22 · 2022: 28 · 2021: 40 · 2020: 30 · 2019: 25 · 2018: 27 · 2017: 27 · 2016: 24 · 2015: 29 · 2014: 32 · 2013: 27 · 2012: 25
FWCI
19.23
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
Funders
  • Samuel Waxman Cancer Research Foundation
  • American Liver Foundation
  • Pfizer
  • Uehara Memorial Foundation
  • University of Oxford
  • Institució Catalana de Recerca i Estudis Avançats
  • National Institutes of Health
  • University of California, San Diego
  • National Institute of General Medical Sciences (R01GM041804)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK076986, R01DK076920)
  • School of Medicine, University of California, San Diego
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
liver fibrosis, CCR1, CCR5, CC chemokines, MIP-1α, MIP-1β, RANTES, chemokine receptor deficiency, Kupffer cells, macrophage infiltration, PI3K signaling, redox signaling, liver cirrhosis, chimeric mice
MeSH terms
Animals, Cell Movement, Humans, Kupffer Cells, Liver Cirrhosis, Experimental, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Receptors, CCR5, Mice, Receptors, CCR1, CCR5 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review